Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Y-39983. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 7/20 | 1.00 |
| ▸ | ROCK1 known ✓ | Q13464 | 5/20 | 1.00 |
| ▸ | CIT | O14578 | 9/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 2/20 | 1.00 |
| ▸ | PRKACA | P17612 | 2/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 2/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 2/20 | 1.00 |
| ▸ | PKN2 | Q16513 | 2/20 | 1.00 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | PRKCB | P05771 | 1/20 | 1.00 |
| ▸ | PRKCA | P17252 | 1/20 | 1.00 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 1.00 |
| ▸ | MARK3 | P27448 | 1/20 | 1.00 |
| ▸ | BMPR1A | P36894 | 1/20 | 1.00 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 1.00 |
| ▸ | CLK1 | P49759 | 1/20 | 1.00 |
| ▸ | GSK3A | P49840 | 1/20 | 1.00 |
| ▸ | GSK3B | P49841 | 1/20 | 1.00 |
| ▸ | CDK9 | P50750 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Y-39983 SCHEMBL29431274 | 1.00 | CIT (1.00) | CITROCK2ROCK1PRKD3PRKACA | |
| Y-39983 SCHEMBL25685649 | 1.00 | CIT (1.00) | CITROCK2ROCK1PRKD3PRKACA | |
| Y-39983 SCHEMBL29893202 | 1.00 | CIT (1.00) | CITROCK2ROCK1PRKD3PRKACA | |
| Y-39983 SCHEMBL226557 | 1.00 | CIT (1.00) | CITROCK2ROCK1PRKD3PRKACA | |
| Y-39983 SCHEMBL29816387 | 0.99 | ROCK2 (1.00) | CITROCK2ROCK1PRKD3PRKACA | |
| Y-39983 SCHEMBL599801 | 0.99 | ROCK2 (1.00) | CITROCK2ROCK1PRKD3PRKACA | |
| Y-39983 SCHEMBL599800 | 0.99 | ROCK2 (1.00) | CITROCK2ROCK1PRKD3PRKACA | |
| Y-39983 SCHEMBL29666940 | 0.99 | ROCK2 (1.00) | CITROCK2ROCK1PRKD3PRKACA | |
| Y-39983 SCHEMBL1927760 | 0.99 | ROCK2 (1.00) | CITROCK2ROCK1PRKD3PRKACA | |
| Y-39983 SCHEMBL1927761 | 0.99 | ROCK2 (1.00) | CITROCK2ROCK1PRKD3PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 705 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744663-A2 | SKIN COMPOSITION | Eaderm Co., Ltd. (JP) | 2026-05-20 | — | — | EP | claimed |
| WO-2026090172-A1 | CELL CULTURE SYSTEMS COMPRISING MICROPATTERNED ARRAYS AND METHODS OF USE | ALTIS BIOSYSTEMS, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4728051-A1 | STANDARDISING PLURIPOTENT STEM CELLS | United Kingdom Research and Innovation (GB) | 2026-04-22 | — | — | EP | claimed |
| EP-4720261-A1 | NOVEL CULTURE CONDITIONS FOR CLONAL EXPANSION OF NEPHRON PROGENITOR CELLS, GENERATION OF NEPHRON ORGANOIDS, AND RAPID AND SCALABLE MODELING OF POLYCYSTIC KIDNEY DISEASE | University of Southern California (US) | 2026-04-08 | — | — | EP | claimed |
| US-20260076969-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-19 | — | — | US | claimed |
| EP-4709477-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF MICROVASCULATURE DYSFUNCTION AND RELATED DISEASES | The Texas A&M University System (US) | 2026-03-18 | — | — | EP | claimed |
| EP-3843845-B1 | INHIBITION OF PROTEIN KINASES TO TREAT FRIEDREICH ATAXIA | UNIV MASSACHUSETTS (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260053804-A1 | Compositions and Methods for the Restoration of Ciliary Function | UNIV YALE (US) | 2026-02-26 | — | — | US | claimed |
| WO-2025224050-A1 | METHODS OF TREATMENT OF PATIENTS SUFFERING FROM HYPOMELANOSIS OF ITO | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-10-30 | — | — | WO | claimed |
| EP-4638708-A1 | METHOD FOR THE IN VITRO PRODUCTION OF A HEPATOCYTE ORGANOID | Universiteit Utrecht Holding B.V. (NL) | 2025-10-29 | — | — | EP | claimed |
| US-20030165576-A1 | Antitumor effect potentiators | MITSUBISHI PHARMA CORPORATION (JP) | 2003-09-04 | — | — | US | claimed |
| US-20030125351-A1 | Agent for prophylaxis and treatment of glaucoma | AZUMA MITSUYOSHI (JP) | 2003-07-03 | — | — | US | claimed |
| US-20030096843-A1 | Preventives/remedies for kidney diseases | MITSUBISHI PHARMA CORPORATION (JP) | 2003-05-22 | — | — | US | claimed |
| EP-1295607-A1 | ANTITUMOR EFFECT POTENTIATORS | Mitsubishi Pharma Corporation (JP) | 2003-03-26 | — | — | EP | claimed |
| EP-1195372-A1 | N-heterocyclic substituted benzamide derivatives with antihypertensive activity | Mitsubishi Pharma Corporation (JP) | 2002-04-10 | — | — | EP | claimed |
| EP-1177796-A1 | PREVENTIVES/REMEDIES FOR LIVER DISEASES | Mitsubishi Pharma Corporation (JP) | 2002-02-06 | — | — | EP | claimed |
| EP-1174150-A1 | PREVENTIVES/REMEDIES FOR ANGIOSTENOSIS | Mitsubishi Pharma Corporation (JP) | 2002-01-23 | — | — | EP | claimed |
| EP-1163910-A1 | PREVENTIVES/REMEDIES FOR INTERSTITIAL PNEUMONIA AND PULMONARY FIBROSIS | Welfide Corporation (JP) | 2001-12-19 | — | — | EP | claimed |
| EP-1034793-A1 | PREVENTIVES/REMEDIES FOR GLAUCOMA | Senju Pharmaceutical Co., Ltd. (JP) | 2000-09-13 | — | — | EP | claimed |
| EP-0757038-A1 | BENZAMIDE COMPOUND AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-02-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096843-A1 | Preventives/remedies for kidney diseases | RHOA, ROCK1, MMP1 | ROCK2 6/4885ROCK1 2/4885CIT 8/4885 |
| US-20030125351-A1 | Agent for prophylaxis and treatment of glaucoma | ROCK1, PDE3A, RHOA | ROCK2 10/4885ROCK1 1/4885CIT 17/4885 |
| US-20030165576-A1 | Antitumor effect potentiators | RHOT2, ROCK2, CIT | ROCK2 2/4885ROCK1 5/4885CIT 3/4885 |
| US-20260053804-A1 | Compositions and Methods for the Restoration of Ciliary Function | MTCL3, DYNLL2, CEP170 | ROCK2 166/4885ROCK1 282/4885CIT 303/4885 |
| US-20260076969-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | ATP5ME, MT-ATP6, ATP5MK | ROCK2 341/4885ROCK1 238/4885CIT 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.